Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
10.1039/c6tb00882h 13 GorouhiF.MaibachH
In conclusion, whatever medication that increases endogenous portal insulin (signaling) in T2DM patients, regardless of the glucose level (specifically sulfonylurea derivatives and peroxisome proliferatoractivated receptor [PPAR-] agonists, but not dipeptidyl peptidase-4 inhibitor [DPP4i], or glucagonlike peptide-1 [GLP-1] analogues) will lead to an increase in body weight, even when caloric intake is not increased
Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays
Tissue-threshold split receptor density, downstream signal amplification, and per-tissue glucagon sensitivity differ across liver, visceral fat, sinus node, and subcutaneous fat
